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Abstract 
Background: The impact of the coronavirus disease 2019 (COVID-19) 
pandemic on people with multiple sclerosis (MS) is a major current 
concern, in particular the risk of death. Here we describe the impact of 
the first wave of COVID-19 infections (Mar 2020-July 2020) on the 
Scottish MS Register (SMSR) population, a cohort of 4702 individuals 
with MS, all newly diagnosed in the past decade. 
Methods: We established a clinician alert system, linking the SMSR 
with the Electronic Communication of Surveillance in Scotland 
(ECOSS). This allows identification of patients within this cohort who 
had a positive SARS-CoV-2 PCR test. The SMSR was also linked to death 
records from National Records Scotland. 
Results: Of 4702 people with MS, 246 severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) PCR tests were performed, of 
which 17 were positive. The proportion of positive tests were similar 
to the general Scotland population (Observed PCR confirmed cases = 
17, expected = 17.5, O/E = 0.97, 95% CI: 0.60 – 1.56, p=.90). Between 1
st March – 31st July 2020 12 individuals on the SMSR died, 5 of which 
were linked to COVID-19 (1 PCR confirmed, 4 clinical diagnoses 
without PCR confirmation). This number of COVID-19-related deaths 
was higher than expected (observed deaths = 5, expected deaths = 
1.2, O/E = 4.03, 95% CI = 1.48 – 8.94, p=.01). All COVID-19-related 
deaths in the SMSR occurred in individuals with advanced disability 
(Expanded Disability Status Scale ≥7), and no deaths occurred in 
patients receiving disease modifying therapy (DMT) therapies. 
Conclusion: In this nationally comprehensive cohort of MS patients 
diagnosed in Scotland within the past 10 years, we observed similar 
rates of PCR-confirmed SARS-CoV-2 infection compared to the general 
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Introduction
Coronavirus disease 2019 (COVID-19), caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
emerged in China in late 2019 and was declared a pandemic by 
the WHO in mid-March 20201,2. An important aspect of the 
public health response to COVID-19 has been the accurate 
identification of individuals at risk of severe COVID-19 
outcomes, particularly those at high risk of death.
Multiple sclerosis (MS) affects over two million people 
worldwide and the impact and mortality of COVID-19 on 
people with MS is a source of major current concern. People with 
multiple sclerosis are potentially at risk of severe COVID-19 
because they are receiving immunosuppressants, may develop 
significant disability and commonly have comorbidities. Equally, 
many individuals with MS are of working age and severe 
COVID-19 avoidance measures may cause social, mental and 
financial harm.
During the first wave of the COVID-19 pandemic guidelines 
were drawn up by national and international neurological 
and MS societies to advise people with MS of their risk of 
severe COVID-19 based on theoretical risks posed by 
immunotherapy, and evidence of respiratory and bulbar failure3,4.
As the first wave of the pandemic has emerged, case series 
and registries of patient-reported and physician-reported 
COVID-19 in people with MS have enabled the identifica-
tion of risk factors for severe COVID-19 outcomes5–8. These 
studies suggest that age, Expanded Disease Severity Score 
(EDSS) and comorbidities are risk factors for severe 
COVID-195–8. These studies also suggest that some immu-
notherapies such as ocrelizumab may confer modest risk for 
severe COVID-19 outcomes, but most immunotherapies do 
not7. Such studies are important for identifying characteris-
tics of affected individuals but rely on spontaneous reporting. 
There is a need to understand the impact of the pandemic 
in a representative cohort where cases are ascertained in an 
unbiased manner, with a focus on severe outcomes and death.
The Scottish MS Register (SMSR) is an NHS Scotland 
audit tool which has collected data on over 4500 newly diag-
nosed individuals with MS in Scotland since 20109. MS is a 
lifelong disease, with a clinical course typically lasting over 
30 years. Therefore, the Scottish MS register is a nationally 
comprehensive, incident cohort of people with relatively early 
MS, in the first decade of disease9. The SMSR can be linked to 
other healthcare databases across Scotland including infections 
and deaths.
In light of the recent COVID-19 pandemic, we linked data 
from the Scottish Multiple Sclerosis Register with the Elec-
tronic Communication of Surveillance in Scotland (ECOSS), a 
Scotland-wide surveillance tool for monitoring infections 
that are of clinical or public health importance. This flagging 
system allows neurologists across Scotland to be informed when 
people with MS under their care develop COVID-19, based 
on a positive nasopharyngeal PCR test. In addition, linkage 
to Scottish death records from National Records Scotland 
was also performed during the period of the pandemic first 
wave.
In this manuscript we report the findings from this surveil-
lance system during the first wave of the COVID-19 pandemic 
in Scotland over the period 1st March – 31st July 2020.
Methods
Scottish MS Register: ethics and data governance
The research and governance framework of the SMSR has 
been previously described9,10. The Scottish MS Register is an 
established Scottish national NHS audit, and as such does 
not require research ethics approval. The aim of the register, 
which was established in 2010, is to improve the NHS care 
of people with MS in Scotland. The aims, objectives, permis-
sions and data governance of the SMSR are available from the 
Register site.
Patient information about how the data is collected and used is 
provided in the Patient Information Sheet.
Linkage to ECOSS and mortality databases
Following internal governance review, the ECOSS and SMSR 
databases were electronically linked in real-time, permitting 
patients appearing on both databases to be identified weekly 
using the Scottish national patient unique identifier system (the 
Community Health Identification number) starting March 1st 
2020. Local neurologists were informed by the SMSR when 
a patient under their care had developed PCR confirmed 
SARS-CoV-2 infection, or had died. This information was used 
in the routine clinical care of the patient and neurologists fed 
back deidentified data to the SMSR. Deaths in the absence 
of a positive COVID-19 PCR results were determined to be 
COVID-19 related in the clinical judgement of the local clini-
cal neurologist. Collated data was reviewed periodically during 
the pandemic.
Comparison of SMSR data with general Scottish 
population
The population structure of the SMSR was taken from https://
www.msr.scot.nhs.uk/Reports/Dashboard-2020.html and was 
cross-referenced with national death records to exclude individuals 
who died prior to 1st March 2020.
National background rates of COVID-19, including mortality 
data, were identified from published PHS datasets. These age 
and sex-specific rates were used to estimate expected number 
of positive tests and deaths within the SMSR. COVID-19 
test data were taken from the Public Health Scotland Weekly 
COVID-19 report dated August 2 and included the period 1st 
March – 31st July 202011. This contains information on all posi-
tive and negative nasopharyngeal COVID-19 tests carried 
through NHS Scotland laboratories and includes results from 
hospitals, GP practices, drive-through centres, mobile units, 
and home testing kits. Data on COVID-19 related deaths from 
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1st March to 31st July 2020 were obtained from the National 
Records of Scotland, defined as deaths occurring in any 
location where COVID-19 was recorded on the death certificate12.
Statistical analyses
Statistical analyses were performed in R version 3.6.3 using 
package epiR version 1.0-15. Confidence intervals were approxi-
mated using the method of Rothman and Greenland assum-
ing observed events to be Poisson variates and expected 
events invariate. Under the same assumptions, p values (H0: ratio 
of observed to expected = 1), were calculated by chi-squared 
test. Exact confidence intervals and hypothesis testing, where 
expected counts were low (≤5), were calculated using the mid-P 
exact method. For reporting statistical significance, the threshold 
(α) was set at 0.05.
Results
(i) PCR-confirmed SARS-CoV-2 cases within the SMSR
Of the 4702 people diagnosed with MS since 2010 on the 
SMSR, 246 (5.2%) underwent SARS-CoV-2 PCR testing during 
the first wave. Over the same period, 6.7% of the Scottish 
population underwent testing. Of the 246 SARS-CoV-2 
PCR tests carried out in the SMSR population, 17 (6.9%) 
were positive (Figure 1). The number of SARS-CoV-2 
PCR-confirmed tests we observed in the SMSR was similar 
to the number expected, based on Scotland-wide testing data. 
(Table 1, observed =17, expected = 17.5 (O/E = 0.97, 95% 
CI: 0.60 – 1.56), X2(d.f. = 1) = 0.014, p=0.90).
(ii) COVID-19-associated deaths within the SMSR
Given that the proportion of PCR-confirmed cases were 
similar between the SMSR and the general population, we next 
asked whether there were differences in COVID-19 related 
mortality. During the first pandemic wave 12 deaths of indi-
viduals on the SMSR were recorded, 5 of which were iden-
tified to be COVID-19 related. This observed number of 
COVID-19-related deaths in the SMSR cohort is higher than 
expected, based on COVID-19 related death rate in the general 
Scottish population over the same time period. (Table 2, observed 
COVID-19 related deaths = 5, expected COVID-19 related 
deaths 1.2, O/E = 4.03, 95% CI = 1.48 – 8.94, p=0.01 (mid-P 
exact)). One individual died after positive PCR-confirmation, and 
Figure 1. Overview of Scottish Multiple Sclerosis (MS) Register coronavirus disease 2019 (COVID-19) surveillance system. 
SARS-CoV2: severe acute respiratory syndrome coronavirus disease 2019, ECOSS: Electronic Communication of Surveillance in Scotland.
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4 died of clinically suspected COVID-19 but were not tested. 
The timings of these deaths relative to the wave of COVID-19 
attributable deaths in Scotland are shown in Figure 2.
In light of the observed excess of COVID-19-related deaths 
over and above the general population we collated clinical infor-
mation fed back to the SMSR about COVID-19 attributable 
deaths. Within the SMSR cohort, all five patients who died 
due to COVID-19 had advanced disability (EDSS≥7) and 
none were receiving disease modifying therapies.
Discussion
Using the Scottish MS Register COVID-19 surveillance system, 
we found that the proportion of SMSR with PCR-confirmed 
SARS-CoV2 infection was similar to that of the general 
Scottish population. However, we observed 5 deaths linked to 
COVID-19, when ~1 death was expected, based on the 
Scottish reference population. These deaths all occurred in 
patients with advanced disability and no patients receiving 
immunotherapy died.
The SMSR was established in 2010 to capture all incident 
MS cases in Scotland. The register therefore has the advan-
tage of being nationally comprehensive and captures data from 
individuals who are in the first decade of the disease, who 
will have lower disability scores, and higher immunotherapy 
treatment rates than the prevalent population13.
Our data provide particular insight into the impact of 
COVID-19 on mortality within the SMSR and suggest that 
Table 1. Number of PCR-confirmed SARS-CoV2 positive cases in Scottish MS Register March 1st 2020 – 31st July 2020, 
compared to Scotland-wide SARS-CoV-2 positive PCR test results.
Sex Age SMSR 
population
Positive COVID-19 
tests in Scotland 
(per 1000 population)
Expected positive 
COVID-19 tests in 
SMSR
Observed positive 
COVID-19 tests in 
SMSR
O/E 
(95% CI)
Female 15-44 1524 3.54
13.8 1345-64 1494 4.89
65-84 261 4.25
Male 15-44 647 1.59
3.7 445-64 659 3.14
65-84 116 5.06
Total
17.5 17
0.97 (0.60 – 1.56) 
p=0.90
MS: Multiple Sclerosis, SARS-COV-2: Severe acute respiratory syndrome coronavirus 2, SMSR: Scottish MS Register, COVID-19: coronavirus disease 
2019, O/E: observed/expected
Table 2. Number of COVID-19 related deaths in Scottish MS Register March 1st 2020 – 31st July 2020, compared to 
Scotland-wide results.
Sex Age SMSR 
population
COVID-19 deaths in 
Scotland 
(per 1000 population)
Expected 
COVID-19 deaths in 
SMSR†
Observed 
COVID-19 related 
deaths in SMSR
O/E 
(95% CI)
Female 15-44 1524 0.01
0.71 245-64 1494 0.16
65-84 261 1.76
Male 15-44 647 0.01
0.52 345-64 659 0.31
65-84 116 2.70
Total 1.24 5 4.03 (1.48 – 8.94) p=0.01
†Unrounded values sum to total.
MS: Multiple Sclerosis, SMSR: Scottish MS Register, COVID-19: coronavirus disease 2019, O/E: observed/expected
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this burden is falling upon patients with advanced disability. 
However, our analysis has a number of important limita-
tions. Firstly, during the majority of the time period covered by 
this analysis, SARS-CoV2 PCR swab testing was restricted to 
a hospital setting or healthcare workers. Throughout the first 
wave of COVID-19 infection the availability of SARS-CoV2 
PCR nasopharyngeal swab tests changed, as did the thresh-
old for testing: initially only hospitalised patients were eligi-
ble for tests, followed by healthcare professionals, and finally 
widespread community testing was introduced. Therefore, 
many mild cases occurred in the community without PCR 
confirmation and would not be identified using this surveillance 
system. Secondly, while the ECOSS database is comprehen-
sive, we cannot be sure that all cases are captured through 
record linkage, such as those having privately organised tests 
or not being tested at all. Thirdly, the data linkage described 
occurs within Scotland only and will not capture COVID-19 
diagnoses or deaths outside Scotland. Finally, since the SMSR 
is primarily an audit tool, detailed clinical data such as severity 
scores and immunotherapy details are not currently collected 
across the SMSR.
Caution is also needed in interpretation of our observed 
versus expected analyses for COVID-19-related deaths because 
of slight differences in ascertainment between SMSR and 
National Records Scotland. In the general Scottish popula-
tion, a COVID-19-related death is defined by National Records 
of Scotland as a death which records COVID-19 on the death 
certificate. In the SMSR population, a death was recorded as 
COVID-19-related by the neurologist.
These results are consistent with an emerging body of 
evidence derived from other cohort and registry studies which 
suggest that the burden of severe COVID-19 is falling on 
individuals with advanced disability rather than those receiv-
ing immunotherapies5,6. Our data do not permit quantifica-
tion of the risk of death with individual immunotherapies since 
the SMSR holds only very limited data on the current DMT 
usage of the population, although over 60% of newly diag-
nosed patients in the SMSR are offered a DMT at the point of 
diagnosis9. While it is reassuring that no patients on DMTs in 
the SMSR cohort died of COVID-19 it is important to bear in 
mind that UK Government and Scottish Government advice 
was for all patients with MS to perform stringent social 
distancing during much of the period captured here. 
These results may be relevant to informing the optimisa-
tion of COVID-19 avoidance measures for people with MS in 
Figure 2. PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases and coronavirus disease 2019 
(COVID-19) related deaths during the first pandemic wave. PCR-confirmed SARS-CoV2 cases (blue) and COVID-19-related deaths 
(red) within the Scottish Multiple Sclerosis (MS) Register (top) and Scottish population (bottom). Cases are described in weeks, beginning 1st 
March 2020 (week 1) and ending the week 26th July 2020.
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the event of future pandemic waves. In Scotland during 
the first wave of the pandemic, all patients with MS were 
advised to perform particularly stringent social distancing. In 
addition, people with MS who (i) had recently received treat-
ment with alemtuzumab or cladribine or (ii) experienced bulbar 
or respiratory dysfunction, were advised to adopt even more 
stringent “shielding” measures. Our analysis is not intended 
to evaluate the complex risk-benefits outcomes of such inter-
ventions. However, it is clear that, within the SMSR cohort, 
those with advanced neurological disability are a particularly 
vulnerable population.
Conclusion
The number of confirmed SARS-CoV-2 infections in the 
SMSR were observed at a similar frequency to the general 
population. However, we observed a small number of excess 
deaths due to COVID-19 in people with MS compared to the 
general population. These deaths occurred in individuals with 
advanced disability who were not receiving immunotherapy. 
These results may help identify people with MS who are 
vulnerable to severe/fatal COVID-19.
Data availability
Source data
COVID-19 data
Scotland-wide COVID-19 PCR test data are available online 
from Public Health Scotland (https://publichealthscotland.
scot/). The specific dataset used is the “Public Health Scotland 
Weekly Covid-19 Report August 9” (Supplementary Excel File, 
Tab = Positive AgeSexSIMD); https://beta.isdscotland.org/find-
publications-and-data/population-health/Covid-19/Covid-19-sta-
tistical-report/. [Accessed: 16-Aug-2020]).
Scotland-wide COVID-19 related mortality data are available 
online from the National Records of Scotland (https://www.
nrscotland.gov.uk/). The specific dataset used is the “Deaths 
involving coronavirus (COVID-19) in Scotland Week 31”; 
https://www.nrscotland.gov.uk/files/statistics/covid19/covid-
deaths-report-week-31.pdf. [Accessed: 16-Aug-2020].
Scottish MS Register
This dataset is held within Public Health Scotland (PHS). 
All personal details on the register are stored in accordance with 
Information Services Division (ISD) Guidelines. The most recent 
Scottish MS Register report and publicly available data are 
available from: https://www.msr.scot.nhs.uk/Reports/Dashboard-
2020.html. Full details of data governance can be found here: 
https://www.msr.scot.nhs.uk/data.html
The information is collected by the hospital and is collated 
by the Information Services Division (ISD) at NHS Scotland. 
ISD has well established systems to protect the privacy of data 
held on patients and staff. The General Data Protection Regula-
tion (GDPR), the Data Protection Act 2018 and Public Benefit 
and Privacy Panel for Health & Social Care (PBPP) Guidelines. 
Application for access to data from the SMSR can be made 
to nss.isdscottishmsregister@nhs.net. No identifiable informa-
tion will be passed to any individual or organisation outwith 
the National Health Service.
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This very clearly written report describes rates of Covid infection, and Covid-related mortality, in 
individuals with multiple sclerosis (MS) on the Scottish MS Register (SMSR) during the first wave of 
Covid infections (March 2020-July 2020).  
The study concludes that individuals on the SMSR had similar rates of PCR-confirmed SARS-CoV2 
infections as the general population. But that there was a small number of excess Covid-related 
deaths (n=5), all of which occurred in individuals with advanced disease and high levels of 
disability (EDSS >7.0), who were not receiving DMTs. These findings agree well with other reports.  
The main strength of this study is the unique SMSR resource, and how this was linked by the 
research team to an electronic surveillance system for SARS-CoV2 testing results, as well as deaths 
reported to the National records registry.  
As pointed out by the authors, the study has a number of limitations (most of which are beyond 
the control of the research team), including:
Limited PCR testing during the first wave (meaning that mild community cases would not 
have been identified) and the fact that 4 out of the 5 Covid-related deaths were diagnosed 
clinically. It is also unclear to me why Covid-relatedness for the SMSR cohort was 
determined by a neurologist rather than by the death certificate (as would be the case for 
the general population). This may have introduced bias.  
 
1. 
Limited clinical details held by the SMSR (which is primarily an audit tool) - for example 
regarding use of DMTs, co-morbidities and level of disability. Given this, some caution must 
be applied when extrapolating these data to other clinical groups.  
 
2. 
It would also have been interesting for the authors to speculate on how these data may 
have been influenced by the initial shielding guidance given to individuals with MS. For 
example, I am unsure if the authors have access to information regarding what proportion 
of the SMSR cohort would have been advised to shield. But if significant, the risks calculated 
in this manuscript may be an underestimate. It would also be interesting to know what 
proportion of patients with advanced disease were living in a care-home setting. 
3. 
 
 
Page 8 of 12
Wellcome Open Research 2020, 5:276 Last updated: 04 FEB 2021
In conclusion, this is a very interesting paper that makes excellent use of a unique clinical resource 
(SMSR). It adds further weight to the argument that for further waves/future pandemics greater 
emphasis should be placed on protecting individuals with advanced MS and higher levels of 
disability.
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A national epidemiological survey which aims to estimate the risk of COVID susceptibility and 
death in Multiple Sclerosis (MS) employing a national registry of early MS as its population frame. 
 
Scotland enjoys, almost internationally, unique health care system data linkage capacities. The 
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joined up nature of their health care system and almost complete population coverage enables 
rapid comprehensive studies such as this. Its also heartening to see how these facilities can be 
used to immediately inform patient care as evidenced by the flagging system documented in this 
manuscript. 
 
The analysis is a useful contribution which provides data which aligns with earlier, less 
comprehensive reports in this space. 
 
With the rapid evolution of discovery in this space, it would be helpful for these finding to be 
contextualized with the most up-to-date extant literature. 
 
More details regrading the clinical characteristics of the MS registry would be helpful to 
understand the prevalence of known COVID risk factors. Further, details of what proportion of 
patients fall into the UK government's extreme social isolation category would help assess 
whether the calculated risk is an underestimate.  
 
Finally, given the known geographical risk factors for both MS and COVID (which conceivably could 
conflict), a future effort to match controls according to post code (a feasible undertaking) would 
enhance confidence around the risk estimates.
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In this paper, Fernandes and co-workers report outcomes with Covid-19 in a Scottish MS 
population. A great deal of attention has been given to the possible impact of disease-modulatory 
treatments (DMT) for MS on COVID-19 outcomes. However, most existing data comes from 
spontaneous reports, constituting a limitation for extrapolating results on a population level. In 
this study, the Scottish MS registry (SMSR) was linked to an electronic surveillance system for Sars-
CoV2 testing results, as well as deaths reported to the National Records registry. Top line results 
comprise a similar rate of positive Sars-CoV2 testing results as the general population, but 
increased mortality compared to age and sex matched controls. All five deaths reported occurred 
in individuals with a high disability level who were not currently treated with DMT. The authors 
correctly mention certain limitations with the study, such as that a relatively small proportion of 
individuals were tested for Sars-CoV2 with PCR, the reporting system for test results not covering 
testing in private clinics, the fact that four out of five deaths connected to Covid-19 were clinically 
diagnosed and that the SMSR does not include details on DMT and severity scores. In particular, 
without knowledge about disability levels and DMT status, caution must be exerted before 
extrapolating results to other populations that may be structured in a different way. In addition, 
the SMSR includes individuals being diagnosed with MS in the last decade. It is unclear to this 
reviewer if the coverage has been validated by some means. Also, the age structure of the 
reported population is quite high given the disease duration, likely reflecting a delay between 
disease onset and diagnosis. Only age and sex are reported for the five identified deaths, and 
other factors, such as co-morbidity and other concomitant treatments apart from DMTs, may also 
have been of relevance. Nevertheless, population-based studies, such as this, are still rare and the 
presentation of results, statistical methods and resulting conclusions are relevant given the 
available data.
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